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Background: Information from imaging techniques is determinant for suc-
cessful transcatheter aortic valve implantation (TAVI). The feasibility and utility
of Intra-aortic ultrasound (IAUS) to provide complementary information on top of
angiography and trans-oesophageal echocardiography have never been reported.
Methods: In consecutive patients undergoing TAVI in a single university
centre, IAUS was performed before and after balloon angioplasty and after TAVI.
We assessed off-line the dimensions of the aortic annulus, the extent of calcifica-
tion and localisation in relation to the coronary ostia, the quality of valve deploy-
ment and positioning, and compared to angiographic and intra-oesophageal data.
Results: 14 patients underwent TAVI with IAUS; 6 apical and 8 femoral
approach. IAUS was feasible in all patients. On average, each IAUS run lasted 90
seconds. No complications were observed related to IAUS. All 23 runs were suitable
for analysis; 4 baseline, 8 after balloon, 11 after TAVI. Relevant information pro-
vided by IAUS pre-procedure included annulus diameter, presence of extensive
calcifications and their position close to a coronary ostium. Post-balloon, IAUS made
it possible to assess sigmoid mobility. After TAVI, the diameter, area and symmetry
of the prosthesis could be measured and in 1 patient who had had balloon post-
dilatation for aortic insufficiency, an increase in stent was visible by IAUS.
Conclusion: IAUS appears to be safe and feasible during TAVI and provides
additional information on top of angiography and echography. The clinical value
of the incremental information provided by IAUS remains to be determined.
201
Transcatheter aortic valve implantation with the Edwards valve pros-
thesis in patients with contra-indication to surgery but low (<20%)
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Background: Transcatheter aortic valve implantation (TAVI) is performed
in a number of pts with a Log ES<20% due to comorbidities not included in
the calculation of the Log ES but increasing the risk of AVR. The TAVI
results in this sugroup of “lower risk” patients needed to be assessed.
Population and Methods: We retrospectively analysed 177 consecutive
Edwards balloon expandable TAVI patients included between May 2006 and
January 2011 in our center, and compared the clinical characeristics and
results at 30 days and 1 year of two groups according to the Log.ES<20%
(Low risk: LR): n=60 (34%), or 20% (High risk: HR): n=117 (66%). The
transfemoral approach was used in 128 (72.3%).
Results:
Mean Log ES was 11.9±4.9% and 32.2 ±10.3% in the LR and HR groups
respectively. Mediastinal radiotherapy (20%) and porcelain aorta (15%) were
the dominant inclusion factors in the LS group. Patients in the LR group were
younger (80±9 vs 84±5 years, p = 0.003), more often female (70% vs 43.6%,
p = 0.001), with previous stroke (3.3% vs 17.9%, p=0.004) or CABG (5% vs
33.3%, p<0.001). There was no significant difference in NYHA class, pres-
ence of chronic respiratory failure, diabetes, or pre-existent conductive disor-
ders. Procedural success was 100% vs 95.3% (p=0.1) in the LR and HR group
respectively. There was no significant difference in major vascular complica-
tions (5 vs 6%), major acute stroke (3.7 vs 4.4%), permanent pace maker (5
vs 6%) but less AKI class  2 (0% vs 6%, p=0.003) or life-threatening
bleeding (5% vs 19.7%, p=0.03) in the LR vs HR groups and a better safety
end point (6.8% vs 18.6%, p=0.02) and survival at 30-day (0% vs 11.1%,
p<0.04) and 1 year (5 vs 24.8%, p<0.01) in the LR group.
Conclusions: In patients with contra-indication to surgery but low Log ES
(<20%), TAVI is associated with similarly good procedural success and better
safety end point and mortality rates at 30-Day (0%) and 1 year (5%) than in
the regular high risk population.
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Purpose: Lipoprotein-associated phospholipase A2 (Lp-PLA2) predict cardio-
vascular events in patients with coronary artery disease (CAD) and heart
failure (HF) independently of traditional cardiovascular risk factors. Aims of
our study were (1) to assess relationships between Lp-PLA2 levels, cardiac
disease and treatments; (2) to evaluate the association of Lp-PLA2 level with
the severity of CAD and the extracoronary atherosclerosis.
Methods: 494 subjects (69.8% men, 64.2±16.7y) were recruited from a
population scheduled for diagnostic coronary angiography. Lp-PLA2 mass
concentration was assessed in serum with a Plac® – test turbidimetric immu-
noassay. Control Lp-PLA2 values were obtained in 61 healthy subjects (age
44.5±17.6y) without cardiovascular risk factors or cardiac treatment.
Results: In controls, mean Lp-PLA2 was 163±43 μg/L (men: 166±45 μg/L;
women:159±39 μg/L).
Survival in LR and HR groups
© Elsevier Masson SAS. All rights reserved.
 
64 Archives of Cardiovascular Diseases Supplements (2012) 4, 54-66
Etiologies of cardiac disease were ischemic (40%), valvular (22%), HF
with left ventricular dysfunction (14%), aortic aneurysm (7%) and infection
(5%). Lp-PLA2 correlated with age, BMI, smoking, hypertension, total cho-
lesterol, LDL-cholesterol and apoB but not with diabetes, gender, serum cre-
atinine, NYHA status or Lp(a).
Lp-PLA2 were significantly higher in patients with CAD than in patients
without CAD (223±54 vs. 208±52 μg/L, respectively; p<0.007) and higher in
patients with the most extensive angiographic CAD (single=215.2±52 μg/L;
two=222±53 μg/L and three vessels =251.9±53.7 μg/L, respectively; p<0.0001) or
carotid artery disease (No stenosis=218.8±51 μg/L, mild=224±51 μg/L and
severe=231±46 μg/L; p=0.004).
Patients with heart failure, sepsis or aortic aneurysm had increased Lp-
PLA2 levels: 256.2±46.8 μg/L; 226.7±47.3 μg/L; 218.1±8.9 μg/L, respec-
tively, as compared to controls (p<0.0001).
Lp-PLA2 was significantly associated with treatments such as statins and
ACEi/ARA2 but not with – blockers, antiaggregant drugs or diuretics.
Conclusion: This study clearly shows that interpretation of Lp-PLA2
needs a good assessment of cardiac parameters and treatments, especially
statins and ACEi/ARA2. Lp-PLA2 levels are significantly associated with cor-
onary heart disease and with the extension of extra coronary disease.
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Introduction: TAVI represent a new therapeutic option In high-surgical-
risk patients with severe symptomatic aortic stenosis.
Methods: Uni-centre prospective registry was conducted between 01/02/
2010 and 01/02/2011 to evaluate procedural and mid-term outcomes of two
models of prosthesis: Edwards SAPIEN (EDW) implanted via a transarterial
(TF) or a transapical (TA) approach and CoreValve (CoreV).
Primary endpoint was 30 days and 1 year survival without major events
and secondary endpoints was to evaluate benefit (improvement in NYHA
class, quality of life, valve performance) and risk (mortality and major adverse
events during the follow-up period).
Results: Seventy-three patients (56 EDW TF, 10 EDW TA,7 CoreV), aged
83.4±6 years with logistic EuroSCORE =29% (IC 25-33) and STS score
=28% (IC 25-31) were included.
Device success rate was 97,3% and 30-day and 1 year survival without
major events rate was 38% (IC 26-49) and 43% (IC 32-55) respectively.
Severe complications included death (12.3%), tamponade (1.3%), valve
migration (1.3%), stroke (1.3%), vascular complications (2.7%). Pacemaker
was required in 9% (EDW TF), 20% (EDW TA) and 29% (CoreV). At 6
months 88% of patients were in NYHA class II or less. In three groups, mean
aortic gradient decreased from 41.2 mmHg (IC 37.8-44.6) to 9.3 mmHg (IC
8.1-10.6) at 6 months post-TAVI (P<0,002) and aortic valve area increased
from 0.42 cm²/m² (IC 0.39-0.44) to 0.99 cm²/m² (0.87-1.1) (p<0.002). Paraval-
vular leak was absent or minimal in 92% of patients. There was significant
improvement in quality of life: EQ-5D score was improved in 73% of patients
and EVA score in 80% at 6month follow-up.
Conclusions: Our registry showed satisfactory results in terms of feasibility,
short-term hemodynamic and functional improvement after TAVI in inoperable
patients with severe aortic stenosis. Longer term follow-up is necessary to deter-
mine safety and extend the indications for low-surgical-risk patients.
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Objective: to determine clinical and echocardiographic features, managment,
and prognosis of peri aortic abscesses complicating infective endocarditis.
Methodes: we have analysed clinical, microbiological, echocardiographic
datas, therapies and outcoms of cardiac abscesses occuring during infective
endocarditis in patients admitted to our department from january 2006 to january
2010.
Results: Of 56 cases of infective endocarditis, sixteen patients have develloped
aortic abscess . The mean age was 33 years with a male predominance. Heart
failure was noted in all patients. Streptococcus and staphylococcus predominated.
The trans-thoracic echocardiography coupled with trans esophageal echocardig-
raphy made the diagnosis of periaortic abscesse witch was isolate eleven cases and
associated with other complications in five cases. surgery combined with antibiotic
therapy was the standard treatment with variabl surgical delay from 4 days to four
weeks. Hospital mortality in the acute phase concerned the third of patients. The
evolution of survivors at six months was favorable.
Conclusion: Peri-aortic abscess complicating infective endocarditis
increase mortality and morbidity in spite of modern surgical and medical
approach. It requires therefore a strict monitoring of patients presenting infec-
tious endocarditis.
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Purpose: To assess the outcome of transaortic valve replacement (TAVI)
in very high risk patients and identify predictors of 30 days mortality, need for
pacemaker implantation and > grade 2 aortic regurgitation.
Methods: A total of 102 consecutive patients at very high surgical risk
underwent TAVI through femoral (84%), apical (2%) and left subclavian
(14%) access. All patients had pre pre-procedure pan-aortic CT and, pre- and
post-procedure transthoracic echocardiography. Correlates of endpoints were
assessed using a logistic regression model.
Results: Patients characteristics were: age 82±8, female 42%, Euroscore
32±22, STS score 24±12. CoreValve® (76%) and Sapien® (24%) prostheses
were used. The procedure was successful in 96% of cases with 2 per-proce-
dure deaths. At 30 days rates of death, need for pacemaker implantation and
significant aortic regurgitation were 18.6, 27.4 and 36% respectively. Pre-pro-
cedure correlates of events are reported in the table.
Mortality was mainly related to post procedure pulmonary infection (OR
8.4 [95% CI 2.8-25.2]) and renal failure (OR 5.9 [95% CI 2.04-17.6]).
Conclusions: TAVI is associated with a high procedural success rate in
patients at very high surgical risk. Mortality is mainly related to pre-procedure
left ventricular enlargement. The need for pacemaker implantation could be
predicted by pre-procedure atrioventricular conduction abnormalities. In such
patients the use of Sapiens valve and smaller prostheses may be considered.
Aortic regurgitation may be prevented by the use of larger prostheses in
patients with large aortic annulus.
Table – Pre-procedure predictors of events
Death OR
Left ventricular diastolic diameter (per mm) 1.1 [1.01-1.17]
Pacemaker
Prosthesis/annulus diameter ratio (per %) 1.06 [1.01-1.12]
CoreValve vs Sapien 4.3 [0.9-20]
Preprocedure right bundle branch block 9.9 [1.2-79.3]
Aortic regurgitation
Height (per cm) 1.07 [1.01-1.14]
Male gender 3.4 [1.2-10.9]
CT estimated maximal annulus diameter (per mm) 1.18 [0.99-1.14]
